Fig. 3: Identified neural lineage signature genes upregulated in CRPC-NE patients. | Communications Medicine

Fig. 3: Identified neural lineage signature genes upregulated in CRPC-NE patients.

From: Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes

Fig. 3

a Unsupervised hierarchical cluster of 95 differentially genes expressed in Beltran CRPC-NE cohorts. Pathology classification (CRPC vs. CRPC-NE) is indicated in the annotated track next to the heatmap. b GSEA enrichment plots with NES scores and FDR q values shown. *FDR q value <0.05, **FDR q value <0.01, ***FDR q value <0.001. c Hierarchical cluster analysis of 95 differentially expressed neural lineage genes in Aggarwal t-SCNC cohorts. Pathology classification (Pure/Mixed small cell/Adenocarcinoma) and molecular cluster of small-cell and non-small-cell groups is indicated in the annotation track next to the heatmap. d Enrichment plots for neural lineage signature in Aggarwal t-SCNC cohorts with NES scores and FDR q values shown. *FDR q value <0.05, **FDR q value <0.01, ***FDR q value <0.001. CRPC castration-resistant prostate cancer, CRPC-NE castration-resistant prostate cancer with neuroendocrine features, GSEA Gene Set Enrichment Analysis, NES normalized enrichment score.

Back to article page